持续的高尿血症会通过12α-氧BA和肠道微生物群扰乱肠肝循环
Tong Zou1, Ruixiao Zhang2,3, Zeqing Chen3,4
1Women and Children's Hospital, Qingdao University, Qingdao, China.
Frontiers in microbiology
|November 26, 2025
概括
超尿血症 (HUA) 改变胆酸 (BA) 概况,增加肝脏和大肠中的特定BA. 这些变化与肠道微生物群的转变相关,为代谢疾病机制提供了洞察力.
科学领域:
- 代谢学 代谢学 代谢学
- 微生物学 微生物学
- 胃肠病学 胃肠病学
背景情况:
- 高尿路血症 (HUA) 是一个日益严重的全球健康问题.
- 在HUA中胆汁酸 (BAs) 和肠道微生物群之间的相互作用尚未完全理解.
研究的目的:
- 在HUA的老鼠模型中调查BA配置文件的变化.
- 探索这些BA变化与HUA中的肠道微生物群组成之间的关联.
主要方法:
- 建立正常控制和HUA老鼠模型.
- 在肝脏,血清和骨髓中表征BA概况的向代谢组.
- 16S rDNA基因测序用于分析肠道微生物群组成.
主要成果:
- HUA导致肝脏中胆酸 (CA) 的升高.
- 在阴茎内含量中观察到高水平的陶罗胆酸 (TCA),糖胆酸 (GCA) 和氧胆酸 (TDCA).
- 阴茎中12α-氧胆酸的升高与肝脏CA的增加相关.
- 这些BA变化与*Allobaculum*和*Bifidobacterium*属的丰度增加有关.
结论:
- 超尿血症显著影响胆酸代谢和肠道微生物群组成.
- 该研究揭示了与HUA肠道微生物变化相关的特定胆酸流变化.
- 这些发现为与高尿血症相关的代谢疾病的发病提供了新的视角.
相关概念视频
Hepatic Drug Excretion: Enterohepatic Cycling
2.6K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
2.6K
Hepatic Drug Excretion: Influencing Factors
508
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
508
Gastritis-II: Pathophysiology
1.1K
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
1.1K
Peptic Ulcer Disease I: Introduction
719
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
719
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
1.1K
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
1.1K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
162
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
162


